Presented updated positive interim results from the ongoing registration-enabling clinical trial of cosibelimab for the treatment of metastatic cutaneous squamous cell carcinoma at the European Society for Medical Oncology Virtual Congress 2020.

Expect to complete enrollment of the registration-enabling cohort in mCSCC in early 2021 and anticipate reporting top-line results in the second half of the year.

Believe cosibelimab can be a market-disruptive product in the $25 billion PD-(L)1 class based on the planned pricing strategy.

Expanded cash runway through the successful completion of a $20.5 million financing during the third quarter to support the continued development of cosibelimab and the broader oncology pipeline.